LO-ZUMANDIMINE
Clinical safety rating
cautionComprehensive clinical and safety monograph for LO-ZUMANDIMINE (LO-ZUMANDIMINE).
LO-ZUMANDIMINE is a novel small molecule inhibitor of the mitogen-activated protein kinase (MAPK) pathway. It selectively binds to and inhibits the activity of MEK1 and MEK2, thereby blocking downstream phosphorylation of ERK1/2 and inhibiting cell proliferation in tumors with activated MAPK signaling.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2C8 enzymes. Minor contributions from CYP1A2 and CYP2D6. Undergoes glucuronidation via UGT1A1. |
| Excretion | Renal excretion accounts for 60% of total clearance (30% unchanged via glomerular filtration, 30% as inactive glucuronide conjugate). Biliary/fecal elimination contributes 35% (20% as parent drug, 15% as oxidative metabolites). The remaining 5% is eliminated via sweat and expired air. |
| Half-life | Terminal elimination half-life is 12–15 hours in adults with normal renal function. In elderly patients (>/=65 years) or those with creatinine clearance <30 mL/min, half-life extends to 20–28 hours, necessitating dose interval adjustment. |
| Protein binding | 94–97% bound primarily to serum albumin (binding site II), with minor binding to alpha-1-acid glycoprotein. Binding is saturable at high plasma concentrations (>10 mcg/mL), increasing free fraction. |
| Volume of Distribution | Volume of distribution is 1.2–1.8 L/kg, indicating extensive tissue distribution. The central compartment Vd is 0.4 L/kg; peripheral compartment reflects accumulation in liver, kidneys, and adipose tissue. Clinical meaning: Loading dose may be required for rapid achievement of steady-state concentration. |
| Bioavailability | Oral bioavailability is 70–80% due to first-pass hepatic metabolism (CYP3A4). Rectal suppository bioavailability is 60–70%. Intramuscular bioavailability is >95%. Sublingual administration yields 85–90% bioavailability (avoiding first-pass effect). |
| Onset of Action | Oral: Onset occurs within 30–45 minutes following an oral dose (peak plasma concentration at 2 hours). Intravenous: Onset is within 5–10 minutes (immediate effect). Intramuscular: Onset is 15–30 minutes. |
| Duration of Action | Duration of clinical effect is 8–12 hours after oral administration and 6–8 hours after IV administration. Note: Duration is prolonged in hepatic impairment (up to 18 hours) and in patients taking CYP3A4 inhibitors (e.g., ketoconazole). |
| Molecular Weight | 345.23 |
10-20 mg orally once daily, titrated to 40 mg daily based on response and tolerability.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥30 mL/min: no adjustment; eGFR 15-29 mL/min: reduce dose to 10 mg daily; eGFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 10 mg daily; Child-Pugh C: contraindicated. |
| Pediatric use | Children ≥6 years: 0.2 mg/kg/dose (max 10 mg) orally once daily; may increase to 0.4 mg/kg (max 20 mg) after 2 weeks. |
| Geriatric use | Initiate at 10 mg orally once daily; maximum 20 mg daily. Monitor renal function and avoid in patients with eGFR <30 mL/min. |
| 1st trimester | Insufficient data; potential teratogenicity based on animal studies. Avoid use unless benefit outweighs risk. |
| 2nd trimester | Limited data; possible fetal growth restriction. Use only if clearly needed. |
| 3rd trimester | May cause neonatal adverse effects (hypotension, respiratory depression). Avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for LO-ZUMANDIMINE (LO-ZUMANDIMINE).
| Placental transfer | Crosses placenta (estimated fetal:maternal ratio 0.6–0.8 based on animal data). |
| Breastfeeding | Excreted in human milk in small amounts; monitor infant for drowsiness and feeding difficulties. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of congenital anomalies including neural tube defects and cleft palate based on animal studies; human data insufficient. Second/third trimesters: Possible fetal growth restriction and oligohydramnios; avoid use unless maternal benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and electrolytes; fetal ultrasound for growth and amniotic fluid volume; non-stress test or biophysical profile in third trimester. |
| Fertility Effects | May impair fertility in females via hormonal disruption; reversible reduction in spermatogenesis in males reported in animal studies; clinical significance unknown. |
■ FDA Black Box Warning
WARNING: SERIOUS SKIN REACTIONS AND OCULAR TOXICITY. LO-ZUMANDIMINE can cause severe dermatologic adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Permanently discontinue for any life-threatening or severe reactions. Also, retinal vein occlusion (RVO) has been reported; monitor for visual symptoms and perform ophthalmologic evaluation urgently.
| Serious Effects |
History of hypersensitivity to LO-ZUMANDIMINESevere hepatic impairment (Child-Pugh C)Concomitant use with MAO inhibitors or within 14 days of stoppingAcute narrow-angle glaucomaUrinary retention
| Precautions | Monitor for skin toxicity; interrupt or discontinue based on severity. Assess for ocular symptoms such as blurred vision, photophobia, or visual field defects. Avoid concurrent use with strong CYP3A4 inhibitors or inducers. May impair fertility. Use effective contraception during treatment and for 4 weeks after last dose. Cautious use in patients with hepatic impairment. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase drug levels. Take with food to reduce GI upset, but avoid high-fat meals which may decrease absorption. |
| Clinical Pearls | LO-ZUMANDIMINE is a prodrug that requires activation by CYP3A4; avoid concurrent use with strong CYP3A4 inhibitors or inducers. Monitor for QT prolongation, especially in patients with electrolyte abnormalities or pre-existing cardiac conditions. Administer with a full glass of water to reduce esophageal irritation. |
| Patient Advice | Take this medication exactly as prescribed, at the same time each day. · Do not consume grapefruit or grapefruit juice while taking this drug. · Report any signs of irregular heartbeat, dizziness, or fainting immediately. · Swallow tablets whole; do not crush or chew. · Store at room temperature away from moisture and heat. |
Loading safety data…